ecco2R to facilitatE earLy libEration From mechanicAl Ventilation inpatientS With Copd Acute Exacerbation

NCT ID: NCT04147104

Last Updated: 2020-08-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-28
• Study Completion Date: 2023-06-30

Brief Summary

A pragmatic randomised controlled trial to determine whether early Veno-Venous Extracorporeal Carbon Dioxide Removal (VV-ECCO2R) in mechanically ventilated patients with acute exacerbated Chronic Obstructive Pulmonary Disease decreases the days of invasive mechanical ventilation.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a major worldwide health burden. Currently, it is the fourth leading cause of death worldwide, and is the only leading cause of death that is rising, and will likely become the third cause of death by 2020. COPD is characterized by progressive destruction in the elastic tissue within the lung, causing respiratory failure.

Patients with COPD may experience acute exacerbations with severe hypercapnic respiratory failure. Hypercapnia results from acute worsening of expiratory flow limitation caused by the increased small airway resistance with consequent development of dynamic alveolar hyperinflation and intrinsic positive end-expiratory pressure (PEEP). In the most severe cases, these may be refractory to conventional therapies and mechanical ventilation, becoming life-threatening.

Extracorporeal carbon dioxide removal (ECCO2R) represents an attractive approach in this setting. The last decade has seen an increasing interest in the provision of extracorporeal support for respiratory failure, as demonstrated by the progressively increasing number of scientific publications on this topic. In particular, remarkable interest has been focused on extracorporeal carbon dioxide removal (ECCO2R), due to the relative ease and efficiency in blood CO2 clearance granted by extracorporeal gas exchangers as compared to oxygen delivery.

In recent years, a new generation of ECCO2R devices has been developed. More efficient veno-venous (VV)-ECCO2R devices have become available and have replaced the arterio-venous approach, having the advantage of not requiring arterial puncture.

The new VV-ECCO2R devices offer lower resistance to blood flow, have smaller priming volumes, and provide a much more efficient gas exchange with relatively low extracorporeal blood flows (0.4-1 L/min). The technology of these devices is now comparable to that of renal dialysis and has been experimented in several animal and human studies, demonstrating a significant reduction in arterial CO2 and improvement in the work of breathing.

In summary, minimally invasive ECCO2R appears very promising for patients with acute exacerbation of obstructive diseases refractory to conventional treatment, but systematic evaluation is needed to prove its clinical efficacy.

Conditions

Acute Exacerbation of COPD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard-of-care plus invasive mechanical ventilation

Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.

Group Type: ACTIVE_COMPARATOR

Invasive mechanical ventilation

Intervention Type: DEVICE

Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.

ECCO2R plus invasive mechanical ventilation

Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.

Group Type: EXPERIMENTAL

Low flow ECCO2R

Intervention Type: DEVICE

Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as "sweep gas" containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal.

Invasive mechanical ventilation

Intervention Type: DEVICE

Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.

Interventions

Low flow ECCO2R

Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as "sweep gas" containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal.

Intervention Type: DEVICE

Invasive mechanical ventilation

Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18
• Known or suspected aeCOPD that failed NIV that requires invasive mechanical ventilation
• Failed treatment with NIV defined as:
• NIV for at least 2 hours and no more than 24 hours with signs of respiratory distress (respiratory rate > 30 breaths/min and use of accessory muscles or paradoxical abdominal movements) AND
• PaCO2> 55 mmHg and pH < 7.25 or pH < 7.30 and PaCO2 > 55 mmHg, with PaCO2 decrease < 20% from baseline

• Known or suspected aeCOPD patients where NIV is contraindicated and need immediate invasive mechanical ventilation due to:
• Respiratory arrest
• Inability to protect the airway (impaired cough or swallowing or massive aspiration or respiratory pauses with loss of consciousness or gasping of air)
• Inability to clear secretions
• Agitated and confused patients
• Facial deformities or conditions that prevent mask from fitting
• Uncooperative or unmotivated patients

Exclusion Criteria

• Participation in other interventional studies
• Patients already included in this study that need a new readmission because of a new aeCOPD episode
• aeCOPD intubated > 12 hours
• Extubation within the previous 48 hours following intubation and invasive mechanical ventilation due to any cause
• Anatomical abnormalities or vascular diseases preventing the correct insertion of the ECCO2R cannula
• PaO2 to FiO2 ratio < 150 on PEEP ≥ 5 cmH2O
• Known or suspected pregnancy (women of childbearing potential require a pregnancy test)
• Hemodynamic instability defined as

• MAP < 60 mmHg despite the infusion of fluids or vasoactive drugs OR
• Failure to increase systolic blood pressure above 80-90 mmHg OR
• Need for inotropic drugs to maintain systolic blood pressure> 85 mmHg OR
• ECG evidence of ischemia or significant uncontrolled ventricular arrhythmia
• Acute multiple organ failure defined as more than two organ failures assessed by SOFA score. Organ dysfunction can be identified as an acute change in total SOFA score > 2 points
• Decompensated heart failure defined as an exacerbation of symptoms or signs after a period of relative stability such as dyspnea, fatigue or edema in the setting of previously established myocardial dysfunction (systolic or diastolic)32 and B-natriuretic peptide more than100 ng/L.
• Tracheostomized patients
• Untreated pulmonary embolism, pleural effusion, pneumothorax or bronchopleural fistula as the primary cause of acute respiratory failure
• Hemoglobin < 7 gr/dL that require daily transfusion to maintain hemoglobin above 7 gr/dL at the time of screening
• Active major bleeding defined as35:

• Fatal bleeding
• Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, in a non-operated joint, or intramuscular with compartment syndrome, assessed in consultation with the MD
• Extrasurgical site bleeding causing a fall in hemoglobin level of 2 gr/dL or more or leading to transfusion of two or more units of whole blood or red cells, with temporal association within 24-48 hours to the bleeding
• Recent major surgery in the last 2 weeks
• Platelet count < 50 000/mm3
• Prothrombin time-international normalized ratio (INR) > 1.5 in the absence of anticoagulation therapy
• Heparin-induced thrombocytopenia (HIT) or known paradoxical/allergic reactions to heparin
• History within the previous 3 months of stroke or severe head trauma or intracranial arterio-venous malformation, or cerebral aneurysm, or central nervous mass lesion or intracranial bleeding
• Epidural catheter in place or plan to insert an epidural catheter during the study
• Gastrointestinal bleeding within the 6 weeks prior to study entry
• Severe liver insufficiency (Child-Pugh scores >7) or INR > 1.6 suspected to be related to liver disease (liver associated coagulopathy)
• Presence of severe (acute or chronic) renal failure defined as requiring any form of dialysis (including CRRT and CVVH) and/or having a serum creatinine > 2.5 mg/dL and urine clearance < 20 mL/hour
• Inability to receive blood products
• History of complications from extracorporeal support
• Permanent home ventilation except for sleep-disordered breathing
• Significant weakness or paralysis of respiratory muscles due to causes unrelated to aeCOPD
• Recent (< 7 days) prolonged (> 24 hours) use of muscle paralyzing agents
• Immunocompromised state defined as

• Received chemotherapy or radiation within the previous 45 days and still under treatment for the underlying cancer
• Received or currently receiving immunosuppressive therapy, excluding corticosteroids, within the last 3 months
• Known to have AIDS defined illness
• Patients not expected to survive 6 months on the basis of premorbid health status
• History of uncontrolled, major psychiatric disorder
• Therapeutic restriction (DNR), moribund patient or not expected to survive current hospitalization
• Consent declined

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospital Quiron Sagrado Corazon

OTHER

Sponsor Role: lead

Responsible Party

Luis Morales

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antonio Artigas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari Sagrat Cor, Grupo Quironsalud

Central Contacts

Luis Morales, MD

Role: CONTACT

luchomq2077@gmail.com

+ 34 648493973

References

Del Sorbo L, Pisani L, Filippini C, Fanelli V, Fasano L, Terragni P, Dell'Amore A, Urbino R, Mascia L, Evangelista A, Antro C, D'Amato R, Sucre MJ, Simonetti U, Persico P, Nava S, Ranieri VM. Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med. 2015 Jan;43(1):120-7. doi: 10.1097/CCM.0000000000000607.

Reference Type: BACKGROUND

PMID: 25230375 (View on PubMed)

Burki NK, Mani RK, Herth FJF, Schmidt W, Teschler H, Bonin F, Becker H, Randerath WJ, Stieglitz S, Hagmeyer L, Priegnitz C, Pfeifer M, Blaas SH, Putensen C, Theuerkauf N, Quintel M, Moerer O. A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest. 2013 Mar;143(3):678-686. doi: 10.1378/chest.12-0228.

Reference Type: BACKGROUND

PMID: 23460154 (View on PubMed)

Other Identifiers

2019/53-UCI-HUSC

Identifier Type: -

Identifier Source: org_study_id